Sofinnova set to back dozens of biotechs with €1.2B across strategies
European firm to invest fresh cash across all company stages amid changes in LP base, portfolio composition
European firm Sofinnova expects to make up to 60 new investments from a €1.2 billion pool of capital raised in the past year, spanning four of its seven investment strategies across early- and late-stage life sciences companies.
Sofinnova Partners’ Antoine Papiernik told BioCentury that the firm expects to hold final closes in each strategy by year-end, with the final figure growing beyond €1.2 billion ($1.3 billion). Citing regulations, he declined to name which four strategies have raised new cash...
BCIQ Company Profiles